WebApr 14, 2024 · The drug is an oral inhibitor of the galectin-3, which has shown promise in modifying the tumor microenvironment and reversing the drug resistance brought in by the activity of galectin-3. GB1211 is also being clinically assessed in liver fibrosis. Likewise, many other galectin inhibitors are also being evaluated in different liver diseases. WebNov 30, 2024 · A fast-growing body of data points to galectin-3 (Gal-3) — an adhesive cell surface protein—as a potential therapeutic target for reducing cardiovascular morbidity and mortality. There are now hundreds of published pre-clinical and observational human studies indicating that Gal-3 is both a predictive biomarker and treatment target in CVD ...
National Center for Biotechnology Information
Web1 day ago · Moreover, presence of the galectin-3 inhibitor lactose dose-dependently inhibited the secretion of cathepsin-B (Fig. 5E) and MMP-13 (Fig. 5F) as well as invasion (Fig. 5G) of HT29-I cells but had ... WebApr 13, 2024 · The data to be presented at AACR suggests that both selective inhibition of galectin-1 and dual inhibition of galectin-1 and galectin-3 could provide potential … jamestown college baseball north dakota
Galectin Inhibitors Drugs Companies Clinical Trials Insight 2024
WebGalectin-3 inhibition may reduce pathological microglial neuroinflammation. Novel BBB penetrant inhibitors may need to be developed. Aging and related health concerns: … Web23 hours ago · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis; (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 … WebIn conclusion, the present study revealed that MCP, a galectin‑3 inhibitor, reduced the size of atherosclerotic lesions by inhibiting the adhesion of leucocytes to endothelial cells. Inhibition of galectin‑3 function may be a therapeutic strategy for the treatment of atherosclerosis. MeSH terms Animals Apolipoproteins E / deficiency* james worthy nba teams